|1.||Li, C: 7 articles (07/2001 - 01/2000)|
|2.||Wallace, S: 7 articles (07/2001 - 01/2000)|
|3.||Li, Chun: 6 articles (06/2011 - 02/2002)|
|4.||Singer, Jack W: 5 articles (01/2011 - 03/2005)|
|5.||Ke, S: 5 articles (07/2001 - 01/2000)|
|6.||Wen, Xiaoxia: 4 articles (06/2011 - 01/2004)|
|7.||Oldham, Fred B: 4 articles (01/2011 - 06/2008)|
|8.||Milas, L: 4 articles (07/2001 - 01/2000)|
|9.||Charnsangavej, C: 4 articles (07/2001 - 01/2000)|
|10.||Safran, Howard: 3 articles (10/2014 - 08/2006)|
03/01/2003 - "PG-TXL dramatically improved tumor radioresponse, reducing TCD(50) of single-dose irradiation from 53.9 (52.2-55.5) Gy to 7.5 (4.5-10.7) Gy, an enhancement factor (EF) of 7.2. "
07/01/2000 - "Furthermore, combined radiation and PG-TXL produced a significantly greater tumor growth delay than treatment with radiation and TXL when both drugs were given at the same equivalent TXL dose of 60 mg/kg 24 h after tumor irradiation (enhancement factors, 4.44 versus 1.50). "
12/01/2008 - "A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study."
01/01/2000 - "Thus, the antitumor activity of PG-TXL observed in preclinical studies may be attributed in part to enhanced tumor uptake of PG-TXL."
01/01/2000 - "In preclinical studies, PG-TXL has shown significant antitumor activity against a variety of solid tumors. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/01/2004 - "Based on the promising results in phase I/II studies, 3 phase III trials of CT-2103 were initiated in advanced non-small-cell lung cancer (NSCLC). "
03/01/2005 - "Based on these results, three ongoing randomized phase III trials were initiated to test the efficacy of paclitaxel poliglumex in patients with advanced non-small cell lung carcinoma."
11/01/2005 - "The objectives of this open-labeled, multicenter, phase II trial were to evaluate response, survival, and tolerability in patients at high risk (Eastern Cooperative Oncology Group performance status [PS] of 2 or age >or= 70 years) with advanced-stage non-small-cell lung cancer (NSCLC) receiving single-agent paclitaxel poliglumex as first-line monotherapy. "
04/01/2007 - "Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer."
06/01/2002 - "Phase II clinical trial of XYOTAX in non-small cell lung cancer to continue."
|3.||Breast Neoplasms (Breast Cancer)
08/01/2007 - "Although CT-2103 had activity in this small study of women with HER2-negative metastatic breast cancer, neurotoxicity and hypersensitivity reactions were more frequent in this patient population than expected. "
01/01/2000 - "The purpose of this study was to compare the pharmacological action of PG-TXL and free paclitaxel in a panel of breast cancer cell lines with emphasis on their ability to induce apoptosis, their effects on cell cycle progression, and their cellular uptake. "
01/01/2000 - "Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells."
08/01/2007 - "Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions."
08/01/2007 - "This study evaluated the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-L-glutamate, in patients with HER2-negative, metastatic breast cancer who had received 0 or 1 prior lines of chemotherapy. "
|4.||Melanoma (Melanoma, Malignant)
03/24/2011 - "Biodistribution studies showed significantly higher uptake of SAAC((99 m)Tc)-PSBP-6 in B16/F10 melanoma treated with poly(L-glutamic acid)-paclitaxel than untreated tumors (4.06 ± 0.55% ID/g vs 1.61 ± 0.33% ID/g, P = 0.00011). "
11/01/1997 - "Murine melanoma cells were treated with various concentrations (0.1 microgram, 1.0 microgram, 4.0 micrograms, and 8.0 micrograms/ml) of paclitaxel alone, PG alone, or PG-TXL for 2 hr and 4 hr and harvested immediately without recovery. "
11/01/1997 - "Paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line."
11/01/1997 - "The purpose of this study was to demonstrate the effects of paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel (PG-TXL), on chromosome morphology, telomeric associations, and induction of cell death in a murine melanoma cell line (K-1735 clone X-21). "
01/01/1999 - "The purpose of this study was to investigate and compare the effects of paclitaxel and its water-soluble conjugates (sodium-pentetic acid-paclitaxel; polyethylene glycol-paclitaxel, and poly[L-glutamic acid]-paclitaxel) on chromosome morphology and induction of apoptosis in a metastatic murine melanoma cell line (K1735 clone X-21). "
11/15/2004 - "Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma."
07/06/2001 - "Mice bearing 8-mm syngeneic ovarian carcinoma OCa-1 tumors implanted intramuscularly were treated with i.v. injected PG-TXL alone or in combination with single doses of local radiation. "
07/01/2000 - "Here we report that local tumor irradiation enhanced the distribution of PG-TXL given 24 h later to ovarian OCa-1 carcinoma implanted i.m. "
03/01/2003 - "Mice bearing 7-mm-diameter ovarian carcinomas were treated with PG-TXL at an equivalent paclitaxel dose of 80 mg/kg, single dose or 5 daily fractions of radiation or both PG-TXL and radiation. "
02/01/2002 - "Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma."
|2.||paclitaxel poliglumex (XYOTAX)
|3.||Glutamic Acid (Glutamate)
|10.||Prostaglandins A (PGA)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)